Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)

This study is researching whether the use of tocilizumab before the first dose of linvoseltamab will decrease the risk of Cytokine Release Syndrome (CRS) in participants who have Relapsed or Refractory Multiple Myeloma (RRMM) who have already been treated with at least four lines of treatment for their multiple myeloma, including medicines called a proteasome inhibitor, an immunomodulatory drug, and an anti-Cluster of Differentiation (CD) 38 antibody. The aim of the study is to see how safe, tolerable and effective linvoseltamab is when given after tocilizumab. The study is looking at severa

Trial Details

NCT ID

NCT07609940

Phase

PHASE4

Sponsor

Regeneron Pharmaceuticals

Status

RECRUITING

Cancer Type

Multiple Myeloma

Interventions

Linvoseltamab
Tocilizumab

Locations (sample)

Los Angeles, California, United States|34.05223,-118.24368
St. Petersburg, Florida, United States|27.77086,-82.67927
Baton Rouge, Louisiana, United States|30.44332,-91.18747
Bethesda, Maryland, United States|38.98067,-77.10026
Reno, Nevada, United States|39.52963,-119.8138

Key Eligibility Criteria

Disease progression on or after at least 4 prior lines of therapy including a(n) Protease Inhibitor (PI), Immunomodulatory imide Drug (IMiD), and a…
Eastern Cooperative Oncology Group (ECOG) performance status score ≤2
Confirmed progressive disease according to IMWG criteria during or after the most recent line of therapy
Key Exclusion Criteria:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →